Real-life effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in people with Type 2 diabetes (T2D) according to baseline HbA1c and BMI

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085089" target="_blank" >RIV/00023001:_____/24:00085089 - isvavai.cz</a>

Výsledek na webu

<a href="https://link.springer.com/content/pdf/10.1007/s13300-024-01644-0.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s13300-024-01644-0.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13300-024-01644-0" target="_blank" >10.1007/s13300-024-01644-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-life effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in people with Type 2 diabetes (T2D) according to baseline HbA1c and BMI

Popis výsledku v původním jazyce

Introduction: This study aimed to evaluate the effect of baseline body mass index (BMI) and glycated hemoglobin (HbA1c) on the effectiveness and safety of initiating iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) in routine clinical practice. Methods: We pooled patient-level data from 1406 people with inadequately controlled T2D, initiating a 24-week iGlarLixi treatment. Analysis sets were based on baseline BMI and HbA1c. In the BMI set, 894 (64%) people had a BMI &gt;= 30 kg/m(2) and 510 (36%) a BMI &lt; 30 kg/m(2); in the HbA1c set, 615 (44%) people had an HbA1c &gt;9%, 491 (35%) between 8 and 9%, and 298 (21%) &lt; 8%. Results: After initiating iGlarLixi, HbA1c decreased in all participants, with the greatest least-squares mean reduction at 2.15% from baseline to week 24 in those with baseline HbA1c &gt; 9% (using a mixed model for repeated measures). Overall, mean +/- standard deviation body weight decreased by 1.9 +/- 4.8 kg, with the most prominent loss of 2.6 +/- 4.9 kg recorded in people presenting with obesity. Reported hypoglycemia rates were low across all groups. Conclusions: Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.

Název v anglickém jazyce

Real-life effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in people with Type 2 diabetes (T2D) according to baseline HbA1c and BMI

Popis výsledku anglicky

Introduction: This study aimed to evaluate the effect of baseline body mass index (BMI) and glycated hemoglobin (HbA1c) on the effectiveness and safety of initiating iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) in routine clinical practice. Methods: We pooled patient-level data from 1406 people with inadequately controlled T2D, initiating a 24-week iGlarLixi treatment. Analysis sets were based on baseline BMI and HbA1c. In the BMI set, 894 (64%) people had a BMI &gt;= 30 kg/m(2) and 510 (36%) a BMI &lt; 30 kg/m(2); in the HbA1c set, 615 (44%) people had an HbA1c &gt;9%, 491 (35%) between 8 and 9%, and 298 (21%) &lt; 8%. Results: After initiating iGlarLixi, HbA1c decreased in all participants, with the greatest least-squares mean reduction at 2.15% from baseline to week 24 in those with baseline HbA1c &gt; 9% (using a mixed model for repeated measures). Overall, mean +/- standard deviation body weight decreased by 1.9 +/- 4.8 kg, with the most prominent loss of 2.6 +/- 4.9 kg recorded in people presenting with obesity. Reported hypoglycemia rates were low across all groups. Conclusions: Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes therapy

ISSN

1869-6953

e-ISSN

1869-6961

Svazek periodika

15

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

14

Strana od-do

2337-2350

Kód UT WoS článku

001312117900002

EID výsledku v databázi Scopus

2-s2.0-85204152478